

CLAIMS:

1. A method for [controlling the growth and/or development of a cancer] in an animal or avian species said method comprising administering to said animal or avian species an [effective amount] of a [phospholipase inhibitor] or a [functional derivative or homologue thereof.] WD
2. A method according to claim 1 wherein the phospholipase inhibitor or derivative or homologue [reduces] the [levels and/or activities] of a phospholipase to an [extent] to [reduce the growth and/or development of cancer cells.]
3. A method according to claim 1 ~~or 2~~ wherein the growth and/or development of cancer is in an animal.
4. A method according to claim 3 wherein the animal is a human.
5. A method according to claim 1 wherein the [phospholipase inhibitor] [reduces] the volume of cancer in the animal or avian species.
6. A method according to claim 1 wherein the phospholipase inhibitor inhibits more than one type of phospholipase type A₂ (PLA₂).
7. A method according to claim 6 wherein the PLA₂ inhibitor is derived from *Notechis scutatus* or *Notechis ater*.
8. A method according to claim 7 wherein the PLA₂ inhibitor comprises an amino acid sequence substantially set forth in SEQ ID NO:1 or any one of SEQ ID NOs:4 to 11 or 12 to 33.
9. A method according to claim 6 wherein the PLA₂ inhibitor comprises an amino

acid sequence substantially set forth in SEQ ID NO:2 or SEQ ID NO:3.

SUB
#3

10. A method according to any one of claims 1 to 9 wherein the phospholipase inhibitor inhibits secretory PLA₂ which in turn ~~reduces~~ expression of COX2 thereby ~~reducing~~ catalytic conversion of arachidonic acid to prostaglandin.

11. A biological composition useful for the treatment and/or ^{112.1}prophylaxis of cancer in a target animal or bird ~~such as~~ a human, primate, livestock animal or companion animal said composition comprising a PLA₂ inhibitor ~~such as~~ but not limited to the PLA₂ defined by any one of amino acids sequences set forth in SEQ ID NOs: 1 to 11 or 12 to 33 or a ~~derivative, homologue, analogue or functional equivalent thereof.~~ w D

12. A method for controlling the growth and/or development of a cancer in an animal or avian species said method comprising administering to said animal or avian species an effective amount of a PLA₂ inhibitor having an amino acid sequence substantially as set forth in any one or more of SEQ ID NOs: 1 to 11 or 12 to 33 or an amino acid sequence having at least 60% identity to any one or more of SEQ ID NOs: 1 to 11 or 12 to 33 or a functional derivative or homologue thereof which PLA₂ inhibitor or derivative or homologue reduces the level or activity of secretory PLA₂ thereby reducing expression of a genetic sequence encoding a cyclooxygenase or reducing cyclooxygenase activity.

13. A biological composition useful for the treatment and/or prophylaxis of cancer in a target animal or bird such as a human, primate, livestock animal or companion animal said composition comprising a PLA₂ inhibitor ~~such as~~ but not limited to the PLA₂ defined by any one of amino acids sequences set forth in SEQ ID NOs: 1 to 11 or 12 to 33 or a derivative, homologue, analogue or functional equivalent thereof.